Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Acute Leukemias

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

Leukemia volume 26, pages 1195–1202 (2012)Cite this article

Abstract

The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is constitutively activated in primary acute myeloid leukemia (AML) cells, therefore representing a major target for drug development in this disease. We show here that the specific mTOR kinase inhibitor AZD8055 blocked mTORC1 and mTORC2 signaling in AML. Particularly, AZD8055 fully inhibited multisite eIF4E-binding protein 1 phosphorylation, subsequently blocking protein translation, which was in contrast to the effects of rapamycin. In addition, the mTORC1-dependent PI3K/Akt feedback activation was fully abrogated in AZD8055-treated AML cells. Significantly, AZD8055 decreased AML blast cell proliferation and cell cycle progression, reduced the clonogenic growth of leukemic progenitors and induced caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. Interestingly, AZD8055 strongly induced autophagy, which may be either protective or cell death inducing, depending on concentration. Finally, AZD8055 markedly increased the survival of AML transplanted mice through a significant reduction of tumor growth, without apparent toxicity. Our current results strongly suggest that AZD8055 should be tested in AML patients in clinical trials.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. Kolch W, Pitt A . Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev 2010; 10: 618–629.

    Article  CAS  Google Scholar 

  2. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005; 106: 1063–1066.

    Article  CAS  Google Scholar 

  3. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S et al. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010; 24: 1686–1699.

    Article  CAS  Google Scholar 

  4. Sabatini DM . mTOR and cancer: insights into a complex relationship. Nat Rev 2006; 6: 729–734.

    Article  CAS  Google Scholar 

  5. Guertin DA, Sabatini DM . Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9–22.

    Article  CAS  Google Scholar 

  6. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007; 318: 977–980.

    Article  CAS  Google Scholar 

  7. Ruvinsky I, Meyuhas O . Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006; 31: 342–348.

    Article  CAS  Google Scholar 

  8. Gingras AC, Raught B, Sonenberg N . Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807–826.

    Article  CAS  Google Scholar 

  9. De Benedetti A, Graff JR . eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23: 3189–3199.

    Article  CAS  Google Scholar 

  10. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122–1128.

    Article  CAS  Google Scholar 

  11. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296–1302.

    Article  CAS  Google Scholar 

  12. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109: 3509–3512.

    Article  CAS  Google Scholar 

  13. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098–1101.

    Article  CAS  Google Scholar 

  14. Garcia-Martinez JM, Alessi DR . mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008; 416: 375–385.

    Article  CAS  Google Scholar 

  15. Tamburini J, Green AS, Chapuis N, Bardet V, Lacombe C, Mayeux P et al. Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle 2009; 8: 3893–3899.

    Article  CAS  Google Scholar 

  16. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009; 15: 6732–6739.

    Article  CAS  Google Scholar 

  17. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009; 114: 1618–1627.

    Article  CAS  Google Scholar 

  18. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller Jr WH, Borden KL . Molecular targeting of the oncogene eIF4E in AML: a proof-of-principle clinical trial with ribavirin. Blood 2009; 114: 257–260.

    Article  CAS  Google Scholar 

  19. Carroll M . Taking aim at protein translation in AML. Blood 2009; 114: 1458–1459.

    Article  CAS  Google Scholar 

  20. Silvera D, Formenti SC, Schneider RJ . Translational control in cancer. Nat Rev 2010; 10: 254–266.

    Article  CAS  Google Scholar 

  21. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379–382.

    Article  CAS  Google Scholar 

  22. Green AS, Chapuis N, Trovati Maciel T, Willems L, Lambert M, Arnoult C et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010; 116: 4262–4273.

    Article  CAS  Google Scholar 

  23. Tanaka T, Tsudo M, Karasuyama H, Kitamura F, Kono T, Hatakeyama M et al. A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells. J Immunol 1991; 147: 2222–2228.

    CAS  PubMed  Google Scholar 

  24. Copp J, Manning G, Hunter T . TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009; 69: 1821–1827.

    Article  CAS  Google Scholar 

  25. Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR et al. mTOR S2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 2009; 285: 7866–7879.

    Article  Google Scholar 

  26. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009; 421: 29–42.

    Article  CAS  Google Scholar 

  27. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 2011; 2011: 248–259.

    Article  Google Scholar 

  28. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y et al. An ATP-competitive mTOR inhibitor reveals rapamycin-insensitive functions of mTORC1. J Biol Chem 2009; 284: 8023–8032.

    Article  CAS  Google Scholar 

  29. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A et al. Dual inhibition of PI3K and mTORC1/2 signalling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010; 16: 5424–5435.

    Article  CAS  Google Scholar 

  30. Puissant A, Robert G, Auberger P . Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 2010; 9: 3470–3478.

    Article  CAS  Google Scholar 

  31. Sini P, James D, Chresta C, Guichard S . Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy 2010; 6: 553–554.

    Article  Google Scholar 

  32. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7: e38.

    Article  Google Scholar 

  33. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205–213.

    Article  CAS  Google Scholar 

  34. Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 2008; 22: 1698–1706.

    Article  CAS  Google Scholar 

  35. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009; 69: 6232–6240.

    Article  CAS  Google Scholar 

  36. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065–3074.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Manning BD . Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167: 399–403.

    Article  CAS  Google Scholar 

  38. Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM . Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 2011; 117: 4141–4154.

    Article  CAS  Google Scholar 

  39. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70: 288–298.

    Article  CAS  Google Scholar 

  40. Collins BJ, Deak M, Arthur JS, Armit LJ, Alessi DR . In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J 2003; 22: 4202–4211.

    Article  CAS  Google Scholar 

  41. Engelman JA, Luo J, Cantley LC . The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606–619.

    Article  CAS  Google Scholar 

  42. Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011; 17: 4378–4388.

    Article  CAS  Google Scholar 

  43. Gozuacik D, Kimchi A . Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004; 23: 2891–2906.

    Article  CAS  Google Scholar 

  44. Bhutia SK, Kegelman TP, Das SK, Azab B, Su ZZ, Lee SG et al. Astrocyte elevated gene-1 induces protective autophagy. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107: 22243–22248.

  45. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109–1123.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all participating investigators from the GOELAMS. This work was supported by grants from the Ligue Nationale Contre le Cancer (LNCC, laboratoire associé), the Fondation de France (comité leucémies), the Institut National du Cancer (INCa) and the Association Laurette Fugain. We thank Olivier Thibaudeau (Institut Claude Bernard, Faculté de Médecine Paris Diderot, France) for his assistance on histological sample processing. We thank Dr Nabih Azar, Hôpital de la Pitié-Salpétrière, Paris, France, for his contribution to normal hematopoietic cells collection. INSERM U895 / Team 2 is an Equipe Labellisée par la LNCC (2011-2013).

Author contributions

LW and NC performed the research, analyzed the data and wrote the manuscript; AP performed autophagy experiments; TTM and AF performed mice experiments; ASG performed experiments and analyzed the data; CV performed cell cycle analysis; NJ, SP, SG, OH, OH, ICM and PA analyzed clinical and biological data; NI and FD contributed AML patient samples and analyzed clinical data; CL and PM analyzed the data; DB and JT designed the research, analyzed the data and wrote the manuscript.

Author information

Author notes

  1. L Willems and N Chapuis: These authors contributed equally to this work.

  2. D Bouscary and J Tamburini: These authors contributed equally to this work.

Authors and Affiliations

  1. Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France

    L Willems, N Chapuis, A S Green, N Jacque, S Park, F Dreyfus, C Lacombe, P Mayeux, D Bouscary & J Tamburini

  2. Inserm, U1016, Paris, France

    L Willems, N Chapuis, A S Green, N Jacque, S Park, F Dreyfus, C Lacombe, P Mayeux, D Bouscary & J Tamburini

  3. Service de Médecine Interne-UF d'Hématologie, Hôpital Cochin, AP-HP, Paris, France

    L Willems, S Park, F Dreyfus, D Bouscary & J Tamburini

  4. Service d'Hématologie Biologique, Hôpital Cochin, AP-HP, Paris, France

    N Chapuis & C Lacombe

  5. INSERM895, Team 2: Cell Death Differentiation and Cancer, Laboratoire d'Hématologie Clinique et de Transplantation, Centre Hospitalier Universitaire de Nice, Nice, France

    A Puissant & P Auberger

  6. Inserm U699, Faculté de Médecine Xavier Bichat, Paris, France

    T T Maciel, A Fricot & I C Moura

  7. Service d'Hématologie Biologique, Hôpital Charles Nicolle, Rouen, France

    A S Green

  8. Université François Rabelais, UPRES EA3855, CHRU de Tours, Service d'Hématologie Biologique, Tours, France

    C Vignon & O Herault

  9. AstraZeneca Cancer & Infection Research Area, Alderley Park, UK

    S Guichard

  10. Service d'Hématologie, Hôpital Necker-Enfants Malades, AP-HP, Paris, France

    O Hermine

  11. Service des Maladies du Sang, CHU Angers, Angers, France

    N Ifrah

  12. Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS), CHU Bretonneau, Tours, France

    N Ifrah, F Dreyfus & D Bouscary

  13. Hematopoietic Stem Cell Laboratory, Cancer Research UK, London, UK

    D Bonnet

Authors
  1. L Willems
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Chapuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Puissant
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T T Maciel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A S Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Jacque
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Vignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Guichard
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. O Herault
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Fricot
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. O Hermine
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I C Moura
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P Auberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. N Ifrah
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. F Dreyfus
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. D Bonnet
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. C Lacombe
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. P Mayeux
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. D Bouscary
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. J Tamburini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to D Bouscary or J Tamburini.

Ethics declarations

Competing interests

Sylvie Guichard is an employee of AstraZeneca Cancer & Infection Research Area, Alderley Park, United Kingdom.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Willems, L., Chapuis, N., Puissant, A. et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 26, 1195–1202 (2012). https://doi.org/10.1038/leu.2011.339

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.339

Keywords

This article is cited by

Search

Advanced search

Quick links